Aging (Aging-US)’s Post

Interesting study exploring the use of non-invasive device for the collection and analysis of intestinal microbiota in post-weaning pigs https://lnkd.in/efNSf_RB

A Long-Lasting Solution for IBS 🌟 Building on the groundbreaking results from our initial study published in the American Journal of Gastroenterology, we’re thrilled to share the latest findings from our ongoing research at ENBIOSIS Biotechnology. Our initial results showed that the Enbiosis’ AI-powered Personalized Diet significantly reduced IBS Symptom Severity and enhanced microbiome diversity within just six weeks. Now, the six-month and twelve-month follow-ups have confirmed that these benefits are not only sustained but further solidified over time. Remarkably, while the Personalized Diet group maintained their improvements, those on the FODMAP diet regressed back to baseline IBS symptom severity. These findings highlight the long-term efficacy of the Enbiosis’ AI-based Personalized Diet, offering a sustainable and scientifically validated approach to managing IBS. We’re proud to see our innovative solution delivering not just immediate relief but also enduring benefits. Stay tuned for more insights as we continue to unlock the future of IBS management! #IBS #GutHealth #Microbiome #PersonalizedDiet #ENBIOSIS #HealthTech #Innovation #Gastroenterology #AI #LongTermHealth #DietScience #SustainableHealth

Bowel Research UK is committed to funding £250,000 in gut microbiome research, investigating how the microbes within us impact the health of our bowels. Apply now! We are accepting proposals for PhDs or project grants of up to £120,000. Applications will be accepted until 17:00 on the 30th of September 2024. The lead applicant of any proposal must be based at a UK institution. Proposals must focus on the following topics: • Links between the gut microbiome and the immune system and/or nutritional status in the development of bowel disease • The role of the gut microbiome in determining/influencing treatment responses • The gut microbiome as a biomarker of health and as a prognostic, diagnostic or predictive marker of bowel disease • Therapeutically modifying the microbiome to prevent or treat bowel conditions (e.g. FMT, IMT, probiotic, prebiotic or synbiotic therapy. This also includes synthetic biology) • The influence of the microbiome in under-represented clinical conditions of the gut e.g. functional conditions such as diarrhoea, constipation, and diverticular disease • Environmental / microbiome interactions and the causation of bowel disease (e.g. microplastics) To find out more information and apply, please visit https://lnkd.in/d9nTRmk #BowelResearch #Microbiome #GutMicrobiome #Bowels #BowelCancer #BowelDisease #IBD #IBS #Crohns #Stoma #Diverticulitis #LynchSyndrome

Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study Effect of Postbiotic Bifidobacterium longum CECT 7347 on Digestive Health Study Overview This study evaluated the impact of heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) on digestive symptoms in healthy adults. It was a randomised, double-blind, placebo-controlled trial with 60 participants over 8 weeks, followed by a check-in at week 10. Key Methods Researchers measured: Gastrointestinal symptoms using various scales Gut microbiome changes Biochemical markers and physical measurements Any adverse effects Main Findings The study found: Small changes in digestive symptoms overall A significant reduction in total and non-HDL cholesterol in the HT-ES1 group An increase in beneficial gut bacteria linked to butyrate production Stable levels of faecal calprotectin in the HT-ES1 group, while it increased in the placebo group Conclusions HT-ES1 may support gut health by: Boosting butyrate-producing bacteria Maintaining normal faecal calprotectin levels Lowering serum cholesterol Clinical Implications Clinical trials are essential for creating safe treatments. To make these benefits accessible, we offer DocSym, an AI-driven platform that integrates clinical standards and research for healthcare professionals. Enhancing Healthcare Delivery Our mobile apps streamline operations by: Facilitating scheduling and treatment monitoring Supporting telemedicine This helps clinics improve patient care and reduce paperwork. Discover more at aidevmd.com. https://lnkd.in/g7d_ZP3j #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Please register for Hifas da Terra’s next educational webinar ’A Deep Dive into Mycotherapy in Clinical Practice’ Presented by Naturopathic Nutritionist, Tanya Clarke 14th May 2024 - 7:00 PM Do you have a yearning to use mycotherapy with more clients? Are you confused as to how different medicinal mushroom concentrations and formulas can be applied in individual and complex cases? If so, this webinar is for you. Join experienced Mycotherapist Tanya Clarke for an in-depth review of six of her clinical cases. Together we will journey through these detailed case studies and how you might consider applying Hifas da Terra medicinal mushroom formulas for a variety of conditions, ranging from chronic fatigue, eczema, cancer, candida and grief. Through Tanya’s observations you will learn how functional mushrooms and certain strains and combinations can be suitably dosed at different stages of an individual’s quest for health, in order to balance and calm the immune system and ultimately restore emotional equilibrium and vitality. Please click the link to register your spot: https://lnkd.in/epipiZwV

❗ ENDOMETRIOSIS linked to DIET and MICROBIOTA ❗ Endometriosis, affecting 10% of women in their reproductive years, remains poorly understood. Both individual and environmental unexplained factors are implicated in this heterogenous condition. This study aims to examine the influence of a Western diet on endometriosis lesion development in mice and to uncover the mechanisms involved. I'm proud and happy to have been at the beginning of this study now published, work in collaboration with Guillaume Parpex, Louis Marcellin, sandrine chouzenoux and Benoit Chassaing realized at the Institut Cochin with the Université Paris Cité. https://lnkd.in/eEPBCXvj #endometriosis #microbiota #diet #westerndiet #akkermansia

These results are a warning about the long-term effects of 'Elimination Diets.' On the positive side, this is encouraging news for Enbiosis' long-term impact. We are working hard to extend human life and will have more great news soon. For a better future: Enbiosis!.. #integrativehealthpractitioner #integrativehealth #integrativemedicine

🌟 Exciting News Alert! 🌟 📣 We are thrilled to share that BiOkuris' latest paper, titled "Chitin-glucan improves important pathophysiological features of IBS," has been accepted and published in the esteemed "World Journal of Gastroenterology." 🔍 This groundbreaking study unravels the intricate mechanisms by which Chitin-Glucan (CG) addresses the key pathophysiological aspects of Irritable Bowel Syndrome (IBS), including visceral analgesia, intestinal inflammation, gut barrier function, and toxin chelation. 💊 The findings underscore CG's promise as a novel therapeutic strategy for individuals suffering from IBS or IBS-like symptoms, offering hope for improved management and quality of life. 📚 For the full details of our study, click here ➡️ https://lnkd.in/enmP5jwQ 👏We would like to thank the authors (Caroline Valibouze, Caroline Dubuquoy Bisiaux, Philippe Chavatte, Michaël Génin, Veronique MAQUET, Salvatore Modica Amore, Pierre Desreumaux, Christel Rousseaux) for the high quality and quantity of research that went into this paper and the Service public de Wallonie (Caroline Louis) for their support to fostering innovation. 💪 This milestone represents a significant step forward in our mission to revolutionize gastrointestinal health, and endorses our nomination as a finalist for the most innovative ingredients of the year at Vitafoods Europe. We look forward to continuing our journey towards groundbreaking advancements in the field. Any questions? 📧info@biokuris.com   #IBS #innovation #chitinglucan #gastroenterology

Delving into unmet medical needs in IBS and highlighting our patented technology's ability to address multiple pathways in IBS pathophysiology marks a pivotal stride in our innovation journey. Gratitude to all involved in this research and the creation of this insightful article!

🌟 Advancing Gut Health: Bacillus coagulans BCP92 for Diarrhea Management 🌟 We are excited to share the results of our latest research on the efficacy and safety of Bacillus coagulans (Heyndrickxia coagulans) BCP92 for treating diarrhea. This study marks a significant step in demonstrating the therapeutic potential of probiotics in gastrointestinal health. 🔍 Study Highlights: 1️⃣ Efficacy: Reduced onset and frequency of diarrhea in castor oil-induced animal models. Comparable antidiarrheal efficacy to loperamide at high doses. 2️⃣ Safety: Acute and subacute toxicity studies (up to 2,000 mg/kg) confirmed no adverse effects. No abnormalities in clinical signs, behavior, organ histology, or hematological/biochemical parameters. 3️⃣ Cytoprotective Properties: In vitro MTT assays confirmed no cytotoxicity, establishing BCP92 as a safe probiotic candidate. 💡 What This Means: Our findings position B. coagulans BCP92 as a safe and effective natural intervention for managing diarrhea, further supporting its use as a therapeutic and preventive agent in gut health. 📖 Dive deeper into our findings by reading the full study here: We welcome discussions and collaborations to explore the exciting potential of probiotics in healthcare! #Probiotics #GutHealth #DiarrheaTreatment #ScientificResearch #BacillusCoagulansBCP92 #Innovation